Microbial transport company COPAN Diagnostics Inc on Thursday reported the shipment of 5 millionth UTM (Universal Transport Medium) from its new additional 38,000-square-foot manufacturing facility in Carlsbad, CA on 20 October 2020 in the battle against COVID-19.
Within a few months, the additional space has drastically increased the UTM production in the US from a former capacity of several thousand test kits per week to more than 840,000 a week. The transport medium is packaged in a plastic, screw cap tube and maintains organism viability for 48 hours at room or refrigerated temperature, according to the company.
The company's US FDA-cleared transport systems are shipped to hospitals, reference labs and other urgent point-of-care sites to collect specimens from patients being tested for the SARS-CoV-2 virus.
With a goal to hit 1m a week, the company has decided to add additional manufacturing capabilities to serve the healthcare needs.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval